Solid Biosciences Inc.
Business
Solid Biosciences is a life sciences company developing a portfolio of gene therapy candidates for rare neuromuscular and cardiac diseases. Its lead program, SGT-003, uses a proprietary AAV capsid (POLARIS-101) and microdystrophin transgene to treat Duchenne muscular dystrophy and is in Phase 1/2 clinical trials. The company also advances SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, SGT-601 for TNNT2-mediated dilated cardiomyopathy, and platform technologies including novel capsid libraries and manufacturing processes. Solid distributes candidates through clinical trial sites globally and intends to pursue commercial marketing approvals with regulatory agencies including the FDA.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 140 | 96 | 77 | 78 | 59 | |
| General and administrative | 39 | 33 | 28 | 29 | 27 | |
| Total operating expenses | 179 | 130 | 104 | 115 | 86 | |
| Loss from operations | −179 | −130 | −104 | −106 | −72 | |
| Interest income | 10 | 9 | 8 | 3 | 64,000 | |
| Interest expense | 203,000 | −340,000 | −440,000 | — | — | |
| Change in fair value of derivative liabilities | −6 | −5 | — | — | — | |
| Other income, net | 824,000 | 652,000 | 1 | −381,000 | 2,000 | |
| Total other income, net | 5 | 5 | 8 | 20 | 66,000 | |
| Net loss | −174 | −125 | −96 | −86 | −72 | |
| Net loss per share, basic | −1.99 | −3.06 | −4.83 | −10.1 | −10.14 | |
| Net loss per share, diluted | −1.99 | −3.06 | −4.83 | −10.1 | −10.14 | |
| Weighted average shares of common stock outstanding used to compute basic net loss per share | 88 | 41 | 20 | 9 | 7 | |
| Weighted average shares of common stock outstanding, used to compute diluted net loss per share | 88 | 41 | 20 | 9 | 7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 60 | 80 | 74 | 155 | 119 | |
| Available-for-sale securities | 128 | 69 | 50 | 58 | 89 | |
| Prepaid expenses and other current assets | 16 | 8 | 6 | 6 | 15 | |
| Restricted cash, current | 1 | 0 | — | — | — | |
| Total current assets | 205 | 157 | 130 | 220 | 223 | |
| Operating lease, right-of-use assets | 22 | 24 | 27 | 29 | 1 | |
| Property and equipment, net | 4 | 5 | 7 | 10 | 6 | |
| Other non-current assets | 223,000 | 366,000 | 209,000 | 175,000 | 94,000 | |
| Restricted cash, net of current portion | 768,000 | 2 | 2 | 2 | 2 | |
| Total non-current assets | 27 | 31 | 35 | — | — | |
| Total assets | 233 | 189 | 165 | 260 | 232 | |
| Accounts payable | 3 | 4 | 2 | 3 | 4 | |
| Accrued expenses and other current liabilities | 19 | 20 | 10 | 17 | 10 | |
| Operating lease liabilities, current | 2 | 2 | 2 | 2 | 1 | |
| Finance lease liabilities | 0 | 1 | 469,000 | 668,000 | 232,000 | |
| Derivative liabilities | 9 | 3 | 0 | — | — | |
| Total current liabilities | 33 | 30 | 15 | 23 | 24 | |
| Operating lease liabilities, net of current portion | 19 | 21 | 23 | 24 | 275,000 | |
| Total non-current liabilities | 19 | 21 | 24 | — | — | |
| Total liabilities | 53 | 51 | 38 | 49 | 24 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value; 240,000,000 and 120,000,000 shares authorized at December 31, 2025 and 2024, respectively; 78,967,888 and 40,468,141 shares issued and outstanding at December 31, 2025 and 2024, respectively | 79,000 | 40,000 | 20,000 | 20,000 | 7,000 | |
| Additional paid-in capital | 1,138 | 921 | 785 | 774 | 685 | |
| Accumulated other comprehensive income | 52,000 | 47,000 | 15,000 | −68,000 | −45,000 | |
| Accumulated deficit | −958 | −783 | −659 | −563 | −477 | |
| Total stockholders' equity | 180 | 137 | 126 | 212 | 208 | |
| Total liabilities and stockholders' equity | 233 | 189 | 165 | 260 | 232 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization of discount on available-for-sale securities | −2 | −4 | −2 | 233,000 | 1 | |
| Equity-based compensation expense | 17 | 11 | 8 | 8 | 13 | |
| Depreciation and amortization expense | 2 | 2 | 3 | 2 | 3 | |
| Non-cash lease expense | 2 | 2 | 3 | — | — | |
| Non-cash acquired in-process research and development | 0 | 3 | 0 | — | — | |
| Common stock issued as upfront payment for collaboration and license agreement | 0 | 2 | 0 | — | — | |
| Change in fair value of derivative liabilities | 6 | 5 | 0 | — | — | |
| Other | −239,000 | −88,000 | 374,000 | — | — | |
| Prepaid expenses and other current and non-current assets | −8 | −2 | 598,000 | 4 | −9 | |
| Accounts payable | −1 | 2 | −764,000 | −5 | 1 | |
| Change in operating lease liability | −2 | −2 | −2 | — | — | |
| Accrued expenses and other current and non-current liabilities | 4 | 5 | −7 | 6 | −2 | |
| Net cash used in operating activities | −156 | −100 | −94 | −98 | −78 | |
| Purchases of property and equipment | −1 | −654,000 | −2 | −3 | −1 | |
| Proceeds from sale of property and equipment | 85,000 | 5,000 | 0 | 600,000 | — | |
| Proceeds from sales and maturities of available-for-sale securities | 179 | 189 | 129 | 213 | 51 | |
| Purchases of available-for-sale securities | −236 | −204 | −117 | −183 | −141 | |
| Net cash used in investing activities | −58 | −16 | 10 | 59 | −91 | |
| Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions | 190 | 0 | — | — | — | |
| Payments of common stock and pre-funded warrants issuance costs in public offering | −2 | 0 | — | — | — | |
| Proceeds from issuance of common stock and pre-funded warrants in private placement | 0 | 109 | 0 | — | — | |
| Payments of common stock and pre-funded warrants issuance costs in private placement | 0 | −5 | 0 | — | — | |
| Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions | 7 | 18 | 3 | — | — | |
| Proceeds from exercises of common stock options | 6,000 | 457,000 | 0 | — | 41,000 | |
| Employee stock purchase plan purchases | 425,000 | 337,000 | 148,000 | — | — | |
| Payments of principal portion of finance lease obligations | −723,000 | −473,000 | — | — | — | |
| Net cash provided by financing activities | 194 | 122 | 3 | 75 | 135 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −20 | 6 | −81 | 36 | −34 | |
| Operating cash flows for operating leases | 4 | 4 | 5 | — | — | |
| Operating cash flows for finance leases | 91,000 | 469,000 | 375,000 | — | — | |
| Financing cash flows for finance leases | 723,000 | 340,000 | — | — | — | |
| Common Stock Issued As Payment For Developmental Milestone Consideration | 5 | 0 | — | — | — | |
| Right-of-use assets obtained in exchange for operating lease liabilities | 0 | 407,000 | 121,000 | 29 | 310,000 | |
| Decrease in right-of-use asset and lease liability due to lease termination | 0 | −261,000 | −252,000 | −464,000 | −1 | |
| Property and equipment purchases included in accounts payable and accruals | 46,000 | 0 | 76,000 | 527,000 | 104,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Solid Biosciences Inc.'s CIK number?
Solid Biosciences Inc.'s SEC CIK number is 0001707502 (1707502). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Solid Biosciences Inc.'s SEC filings?
All of Solid Biosciences Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Solid Biosciences Inc. last report earnings?
Solid Biosciences Inc. (SLDB) most recently filed an earnings 8-K with the SEC on Mar 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-096709). This is Solid Biosciences Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Solid Biosciences Inc.'s most recent earnings 8-K?
Solid Biosciences Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 6, 2026 under accession 0001193125-26-096709. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Solid Biosciences Inc.'s latest earnings 8-K →
Look up any company's CIK number →